脾脏动、静脉组织基质Gla蛋白mRNA的表达在门静脉高压症性血管病变中的意义

The role of expression of matrix Gla protein mRNA in vasculopathy of portal hypertension

目的探讨脾脏动、静脉组织基质Gla蛋白(matrixGlaprotein,MGP)mRNA的表达在门静脉高压症(PHT)性血管病变中的意义。方法光镜及电镜观察对照组和PHT脾脏动、静脉病理形态学改变,采用逆转录-聚合酶链反应(RT-PCR)方法检测MGPmRNA的表达情况。结果光镜与电镜观察下与对照组脾脏血管相比,PHT组的脾脏血管均存在不同程度的平滑肌细胞增生、肥大以及与生物合成有关的细胞器增多;对照组内脾脏动、静脉组织MGPmRNA分别为(0.23±0.10)、(0.26±0.13),PHT组脾动、静脉内MGPmRNA分别为(0.58±0.19)、(0.55±0.15),对照组的显著低于PHT组,P<0.05。结论PHT血管组织MGPmRNA的表达增强,调节血管平滑肌细胞的表型转变、增殖和迁移,并参与了内脏血管病变形成和发展。

Objective To investigate the expression of matrix Gla protein （MGP） mRNA in splenic artery and vein of PHT patients and to discuss its role in the pathogenesis of portal hypertensive vasculopathy. Methods Splenic artery and vein of PHT patients and normal vessels were observed under light and electron microscopy. The expression of MGP mRNA in splenic artery and vein of PHT patients and normal vessels was detected by RT - PCR analysis. Results Compared with normal vessels, hypertrophic and proliferative smooth muscle cells were increased in the splenic artery and vein of PHT patients, and cell organs related to the biosynthesis increased. The expression of MGP mRNA in splenic artery and vein of PHT group was（0.58 ± 0.19）and （0.55 ± 0. 15 ） respectively, significantly higher than that in control group （0.23 ± 0.10） and （0.26 ± 0.13） respectively （ P 〈 0.05 ）, There was no significant difference between the splenic artery and vein in the expression of MGP mRNA in PHT group. Conclusion The increased expression of MGP mRNA in splenic artery and vein of PHT can regulate phenotypic transition, proliferation and migration of VSMC, and contributes to the development of portal hypertensive vasculopathy.